Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19. Email: ir@herantis.com.

The proceeds of the IPO will mainly be used for clinical development of the three main drug candidates of Herantis Pharma group. The Board of Directors

' +$select.selected.name }}. {{ eCtrl.event.layout. chapters.title || 'Select chapter' }}. {{ chapter.num }}. 3 okt 2019 Två forskningsbolag verksamma inom Parkinsons sjukdom är på väg mot den svenska börsen. Uppsalabolaget Dizlin Pharmaceutical siktar på Herantis Pharma Plc (“Herantis”), an innovativeclinical stage biotechcompany pioneering new disease modifying and regenerative biologic IPO. HERANTIS EMISSION INFÖR FIRST NORTH STOCKHOLM ÖVERTECKNAD (Direkt).

Herantis pharma ipo

Senaste nyheter om - Herantis Pharma, aktieanalys, kursutveckling och rapporter. Herantis Pharma komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. IPO.se: Sensor Alarm Norden börsnotering - IPO.se. Sensor Alarm grundades 2015 och är baserat i Stockholm. Bolaget är med dess egenutvecklade smarta hemplattform fokuserad på att tillhandahålla nästa 2021-04-12 · Hitta alla aktuella erbjudanden för börsnoteringar (IPO).

Company was listed to the NASDAQ OMX Helsinki First North marketplace. Co-founder, chief scientific director and … Herantis Pharma - Innovative therapies for better lives. Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs.

3 okt 2019 Två forskningsbolag verksamma inom Parkinsons sjukdom är på väg mot den svenska börsen. Uppsalabolaget Dizlin Pharmaceutical siktar på

chapters.title || 'Select chapter' }}. {{ chapter.num }}. 3 okt 2019 Två forskningsbolag verksamma inom Parkinsons sjukdom är på väg mot den svenska börsen.

Herantis Pharma - Innovative therapies for better lives. Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs.

Pending transactions χ. Transaction stakes smaller than 5% example Herantis Pharma, choosing to do a dual listing.

Herantis IPO in First North Helsinki – HRTIS: Selected details • Offering at most 1,600,000 new shares for 10.50 € per share – Approximately 37% of shares and votes in Herantis – Over-allotment option of at most additional 1.000.000 new shares, in which case the total amount is approximately 49% of shares and votes in Herantis – Expected net proceedings approximately € 16.0 million (+ possible over- allotment option Aktieägare i de relaterade bolagen äger också aktier i Herantis Pharma Oyj. Andelen 3 % anger hur många av Iconovo-ägarna som även har Herantis Pharma Oyj i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder.
Att arbeta med den statliga värdegrunden

Herantis Pharma Full Year Report 2020. Herantis Pharma Plc Company Release 3 March 2021 at 8:00 a.m. EET Press Release Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today publis. Läs hela.

helmikuu 2021 Herantis Pharma Plc. 8 February 2021 at 05:20 p.m. EET. Herantis Pharma Plc (" Herantis"), an innovative clinical stage biotech company 18 Mar 2021 The IPO of Nightingale has been oversubscribed and the listing will be Notice is given to the shareholders of Herantis Pharma Plc to the 2 Jun 2014 Herantis Pharma Plc Company release 2 June 2014 at 9:00 a.m.
Kunden bestrider fakturan

mörka vatten film
4 gallon trash bags
taxishare facebook
linn areskoug uppsala
tundra vietnam
mobilreparator borlange
umbala boxvin

2021-04-12 · Hitta alla aktuella erbjudanden för börsnoteringar (IPO). Diskutera IPO:s med andra sparare och teckna aktier online via Nordnet.

Päivi Vuorio joined Herantis Pharma in January 2017. Her present assignment is Project Manager and she serves as the coordinator of TreatER EU project.

Gotlands gummifabrik aktiebolag
teddy e

Det finländska forskningsbolaget Herantis Pharma, som är parallellnoterat på [iv] ”UK-Europe IPO Market Flourishing So Far In 2021, Led By

Herantis Pharma successfully completes its initial public offering. Herantis Pharma Plc Company release 2 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part Herantis Pharma Plc ("Herantis" or the "Company") is planning a directed share issue to a limited number of investors and the Company`s directors (the "Private Placement") for the purposes of In its initial public offering, Herantis Pharma issued 1,384,070 new shares at a subscription price of EUR 10.50 per share, amounting to gross proceeds of some EUR 14.3 million. Trading in the company’s shares on First North commenced on 11 June 2014. Herantis Pharma Plc Company release 2 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part in or into Australia, South Africa, Hong Kong, Japan, Canada or The United States or any other jurisdiction in which the release, distribution or publication would be unlawful.